Stocks
G1 Therapeutics Financial Statements (GTHX) |
||||||||||
| G1 Therapeuticssmart-lab.ru | % | 2020 | 2021 | 2022 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 24.02.2021 | 23.02.2022 | 01.03.2023 | 14.04.2023 | 28.02.2024 | 08.08.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 45.3 | 31.5 | 51.3 | 51.3 | 82.5 | 58.2 | |||
| Operating Income, bln rub | -96.5 | -142.5 | -136.2 | -136.2 | -39.5 | -37.9 | ||||
| EBITDA, bln rub | ? | -95.5 | -142.5 | -134.9 | -134.9 | -39.0 | -35.4 | |||
| Net profit, bln rub | ? | -99.3 | -148.4 | -147.6 | -147.6 | -48.0 | -44.8 | |||
| OCF, bln rub | ? | -83.7 | -132.1 | -128.6 | -128.6 | -38.3 | -37.5 | |||
| CAPEX, bln rub | ? | 0.000 | 0.000 | 0.506 | 0.506 | 0.000 | 0.000 | |||
| FCF, bln rub | ? | -83.7 | -132.1 | -129.1 | -129.1 | -38.3 | -37.5 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 141.8 | 171.9 | 183.7 | 183.7 | 114.8 | 93.0 | ||||
| Cost of production, bln rub | 0.000 | 2.02 | 3.75 | 3.75 | 7.20 | 6.14 | ||||
| R&D, bln rub | 73.3 | 76.2 | 83.3 | 83.3 | 43.7 | 29.2 | ||||
| Interest expenses, bln rub | 1.78 | 4.67 | 10.4 | 10.4 | 10.0 | 8.94 | ||||
| Assets, bln rub | 228.6 | 254.1 | 188.0 | 188.0 | 121.5 | 98.7 | ||||
| Net Assets, bln rub | ? | -436.1 | -584.5 | 68.7 | 68.7 | 35.4 | 24.6 | |||
| Debt, bln rub | 27.8 | 83.1 | 83.8 | 83.8 | 57.2 | 48.0 | ||||
| Cash, bln rub | 207.3 | 221.2 | 145.1 | 145.1 | 82.2 | 60.8 | ||||
| Net debt, bln rub | -179.5 | -138.1 | -61.3 | -61.3 | -25.0 | -12.8 | ||||
| Ordinary share price, rub | 18.0 | 10.2 | 5.43 | 5.43 | 3.05 | 1.61 | ||||
| Number of ordinary shares, mln | 37.9 | 41.9 | 43.6 | 43.6 | 51.7 | 52.5 | ||||
| Market cap, bln rub | 681 | 428 | 237 | 237 | 158 | 84 | ||||
| EV, bln rub | ? | 502 | 290 | 176 | 176 | 133 | 72 | |||
| Book value, bln rub | -436 | -584 | 69 | 69 | 35 | 25 | ||||
| EPS, rub | ? | -2.62 | -3.54 | -3.38 | -3.38 | -0.93 | -0.85 | |||
| FCF/share, rub | -2.21 | -3.15 | -2.96 | -2.96 | -0.74 | -0.72 | ||||
| BV/share, rub | -11.5 | -13.9 | 1.58 | 1.58 | 0.68 | 0.47 | ||||
| EBITDA margin, % | ? | -210.9% | -452.6% | -263.0% | -263.0% | -47.3% | -60.9% | |||
| Net margin, % | ? | -219.2% | -471.3% | -287.6% | -287.6% | -58.1% | -76.9% | |||
| FCF yield, % | ? | -12.3% | -30.8% | -54.5% | -54.5% | -24.3% | -44.4% | |||
| ROE, % | ? | 22.8% | 25.4% | -214.6% | -214.6% | -135.6% | -182.1% | |||
| ROA, % | ? | -43.4% | -58.4% | -78.5% | -78.5% | -39.5% | -45.4% | |||
| P/E | ? | -6.87 | -2.89 | -1.61 | -1.61 | -3.29 | -1.89 | |||
| P/FCF | -8.14 | -3.24 | -1.83 | -1.83 | -4.12 | -2.25 | ||||
| P/S | ? | 15.0 | 13.6 | 4.62 | 4.62 | 1.91 | 1.45 | |||
| P/BV | ? | -1.56 | -0.73 | 3.45 | 3.45 | 4.46 | 3.44 | |||
| EV/EBITDA | ? | -5.26 | -2.04 | -1.30 | -1.30 | -3.40 | -2.02 | |||
| Debt/EBITDA | 1.88 | 0.97 | 0.45 | 0.45 | 0.64 | 0.36 | ||||
| R&D/CAPEX, % | 16 466% | 16 466% | ||||||||
| CAPEX/Revenue, % | 0.00% | 0.00% | 0.99% | 0.99% | 0.00% | 0 | ||||
| G1 Therapeutics shareholders | ||||||||||
